DAWN vs. MNKD, ARQT, CSTL, LMAT, BDTX, MDGL, ALPN, NUVL, ALKS, and PRGO
Should you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include MannKind (MNKD), Arcutis Biotherapeutics (ARQT), Castle Biosciences (CSTL), LeMaitre Vascular (LMAT), Black Diamond Therapeutics (BDTX), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "medical" sector.
MannKind (NASDAQ:MNKD) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.
49.6% of MannKind shares are held by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 3.0% of MannKind shares are held by insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, MannKind had 2 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 5 mentions for MannKind and 3 mentions for Day One Biopharmaceuticals. MannKind's average media sentiment score of 1.16 beat Day One Biopharmaceuticals' score of 0.77 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media.
MannKind received 541 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 59.87% of users gave MannKind an outperform vote while only 58.18% of users gave Day One Biopharmaceuticals an outperform vote.
MannKind has a net margin of 3.78% compared to MannKind's net margin of 0.00%. Day One Biopharmaceuticals' return on equity of -3.35% beat MannKind's return on equity.
MannKind has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.44, meaning that its stock price is 244% less volatile than the S&P 500.
MannKind has higher revenue and earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.
MannKind currently has a consensus target price of $8.00, suggesting a potential upside of 71.31%. Day One Biopharmaceuticals has a consensus target price of $37.67, suggesting a potential upside of 183.85%. Given MannKind's higher probable upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than MannKind.
Summary
MannKind beats Day One Biopharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Day One Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Day One Biopharmaceuticals Competitors List
Related Companies and Tools
